Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Quattroflow™ to Feature Single-Use Biologic Pumps at INTERPHEX 2013

Published: Monday, January 28, 2013
Last Updated: Sunday, January 27, 2013
Bookmark and Share
Single-use pumps save time and money, and are quick and easy to change.

Quattroflow™ from Almatec® Maschinenbau GmbH, has announced that it will display the latest offerings in its single-use line of pumps for use in biologic-handling applications within pharmaceutical and biotech operations at INTERPHEX 2013 in Booth No. 2463.

The INTERPHEX show, which brings together a wide variety of leaders from the pharmaceutical industry, will be held from April 23-25, 2013, at the Jacob K. Javits Convention Center in New York, NY, USA.

The incorporation of single-use pumps in biologic-handling applications is gaining wider acceptance among pharmaceutical and biotech manufacturers because they can help optimize end-product speed-to-market.

Single-use, or disposable, pumps feature replaceable wetted pump chamber, which is an advantage for manufacturers looking to maximize their production operations.

Quattroflow positive displacement pumps are ideal for single-use systems because they incorporate a four piston-diaphragm technology with no mechanical seals that is driven by an eccentric shaft and motor.

Quattroflow pumps primarily serve the pharmaceutical and biotech industries in applications that require high containment, purity and cleanability, and are best known for transferring shear-sensitive media of aqueous solutions and biological products without damage, ultimately ensuring product safety, efficiency and reliability.

Quattroflow pumps feature wetted pump chambers made of plastic, while the valves are made of EPDM and the diaphragms of EPDM/PP compound.

The Quattroflow product line consists of four sizes - QF150, QF1200, QF4400, QF5050 and QF20K - with capacities of 1 to 20,000 lph (5283 gph).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Madison Researchers Begin Work on Zika Virus
Work will start with basic questions about Zika virus infection.
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
Drug that Activates Innate Immune System Identified
Researchers from the institute have identified a drug, which is straightforward to synthesize and to couple to antigens that induce an immune response and may prove useful in the generation of vaccines.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Protein Protects Against Flu in Mice
The engineered molecule doesn’t provoke inflammation and may hail a new class of antivirals.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!